230 related articles for article (PubMed ID: 3660262)
1. Statewide test of a new postmarketing drug surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
[No Abstract] [Full Text] [Related]
2. Critical reflection on the collection and evaluation of adverse drug reaction data.
Venulet J
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
[No Abstract] [Full Text] [Related]
3. [Is imputation in drug surveillance reliable?].
Girard M
Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
[No Abstract] [Full Text] [Related]
4. Adverse drug reactions.
Turner P
Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
[No Abstract] [Full Text] [Related]
5. [Necessity and difficulties of quantitative drug monitoring].
Lagier G; Dally S; Vincens M; Castot A
Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
[No Abstract] [Full Text] [Related]
6. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
Lagier G; Vincens M; Lefebure B; Frelon JH
Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
[No Abstract] [Full Text] [Related]
7. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
Lagier G; Vincens M; Castot A
Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
[No Abstract] [Full Text] [Related]
8. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
9. The diagnosis of adverse medical events associated with drug treatment.
Stephens MD
Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
[No Abstract] [Full Text] [Related]
10. Revised ADR report permits internal review of drug experience.
Jeffrey LP
Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
[No Abstract] [Full Text] [Related]
11. Potential role of postmarketing research.
Venulet J
Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
[TBL] [Abstract][Full Text] [Related]
12. The desire to regulate: the wish to discover.
Lasagna L
Drugs Exp Clin Res; 1987; 13(11):659-64. PubMed ID: 3443041
[TBL] [Abstract][Full Text] [Related]
13. Advantages of adverse-effect reporting by patients.
Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
[No Abstract] [Full Text] [Related]
14. Measuring adverse drug reactions in a postmarketing surveillance system.
Fisher S; Bryant SG; Kluge RM
Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
[No Abstract] [Full Text] [Related]
15. Rhode Island physicians' recognition and reporting of adverse drug reactions.
Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA
R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
[No Abstract] [Full Text] [Related]
16. Biological indicator test packs: a survey of user practices.
Smith DE
J Healthc Mater Manage; 1988; 6(4):38, 40-2. PubMed ID: 10287653
[No Abstract] [Full Text] [Related]
17. [Critical study of methods of postmarketing drug surveillance].
Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
[No Abstract] [Full Text] [Related]
18. [Information centers on undesirable effects of drugs: also on alerting function].
Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
[No Abstract] [Full Text] [Related]
19. Postmarketing studies of drug efficacy.
Strom BL; Melmon KL; Miettinen OS
Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
[No Abstract] [Full Text] [Related]
20. Early postmarketing drug safety surveillance: data mining points to consider.
Hauben M
Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
